Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055057 | 1.00 | TSHR (0.71) | TSHRACHEHSD17B10CYP19A1ALDH1A1 | |
| Fluoride SCHEMBL27948299 | 0.98 | TSHR (0.68) | TSHRACHEHSD17B10CYP19A1ALDH1A1 | |
| SCHEMBL219410 | 0.84 | CYP19A1 (0.55) | TSHRCYP19A1ALDH1A1CYP3A4ESPL1 | |
| SCHEMBL1026447 | 0.84 | CYP19A1 (0.62) | TSHRCYP19A1ALDH1A1CYP3A4ESPL1 | |
| SCHEMBL1097495 | 0.84 | TSHR (1.00) | TSHRACHEHSD17B10CYP19A1ALDH1A1 | |
| SCHEMBL635130 | 0.84 | TSHR (0.90) | TSHRACHEHSD17B10CYP19A1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27814867 | 0.82 | TSHR (0.49) | TSHRACHEHSD17B10CYP19A1ALDH1A1 | |
| Nitrogen SCHEMBL27917117 | 0.79 | CYP19A1 (0.56) | TSHRCYP19A1ALDH1A1CYP3A4ESPL1 | |
| Benzene SCHEMBL27782128 | 0.79 | CYP19A1 (0.56) | TSHRCYP19A1ALDH1A1CYP3A4ESPL1 | |
| SCHEMBL19026582 | 0.77 | CYP19A1 (0.68) | TSHRCYP19A1ALDH1A1CYP3A4ESPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4007756-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| EP-4426289-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4424838-A2 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | Housey, Gerard M. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118574610-A | AKT3 modulators | 乔治穆内公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-1515562-A | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | - | 2004-07-28 | — | — | CN | disclosed |
| WO-2004039766-A1 | PHENYLETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| CN-1203228-A | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | HOFFMANN LA ROCHE (CH) | 1998-12-30 | — | — | CN | disclosed |
| US-5270309-A | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0303387-B1 | KYNURENIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1993-04-21 | — | — | EP | disclosed |
| EP-0303387-A1 | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | TSHR 3259/4885ACHE 3571/4885HSD17B10 3849/4885 |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | TSHR 3591/4885ACHE 2521/4885HSD17B10 662/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | TSHR 1994/4885ACHE 4819/4885HSD17B10 1116/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | TSHR 4220/4885ACHE 1237/4885HSD17B10 613/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | TSHR 4220/4885ACHE 1237/4885HSD17B10 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.